How Long Does the Meningitis Vaccine Last? Duration of Protection and Booster Guidance for 2026
Medically reviewed by The Online GP by The Wellness Medical Team — Last updated: 24 March 2026
The meningitis B vaccine (Bexsero) provides strong protection for at least 1–2 years after the two-dose course, with antibody levels declining most rapidly in the first 12 months. The MenACWY vaccine lasts approximately 5 years. Neither vaccine provides lifelong protection, and there is currently no routine NHS booster programme for either in the general population. Professor Adam Finn of the University of Bristol has stated that "protection by the vaccine lasts for some years but not forever." The JCVI is reviewing whether adolescent boosters may be needed following the 2026 Kent outbreak. If you were vaccinated years ago and are concerned about waning immunity, a doctor at The Online GP by The Wellness can assess your individual situation and advise on next steps.
Discuss Your Protection — WhatsApp → | Email: team@thewellnesslondon.com
How Long Does MenB (Bexsero) Protection Last?
This is the question on millions of parents' minds right now, and the honest answer is that we do not yet have complete long-term data — because the UK programme only began in 2015. What we do know from clinical studies and real-world monitoring is that antibody levels peak approximately 2 weeks after the second dose and begin declining within the first 12 months. The decline is most rapid in the first year, then slows. Some level of immune memory persists beyond the measurable antibody decline, which means the immune system can mount a faster response if it encounters the bacteria — though whether this residual memory provides reliable protection against invasive disease is not fully established. Dr Bharat Pankhania, senior clinical lecturer in public health medicine at the University of Exeter, has described the vaccine as offering "about 70–90% protection against the most common forms of MenB meningococcal disease, and about 50–70% protection against the most invasive forms." This protection is highest in the months immediately after vaccination and wanes over time. For infants vaccinated at 8 weeks, 16 weeks, and 12 months, the booster at 12 months provides a strong antibody boost that extends protection through early childhood — the period of highest risk. However, as these children grow into adolescence (the second peak of meningococcal risk), their protection may have waned substantially. The oldest children vaccinated under the NHS programme are currently around 10 years old, so we will only know definitively how well infant vaccination protects teenagers as this cohort ages. For adolescents and adults vaccinated with two doses, current evidence supports at least 1–3 years of meaningful protection, with some studies suggesting immune memory may persist longer. The Scientific American, reporting on the Kent outbreak, noted that "the highest levels of protection" from MenB vaccination occur "about one to two years" after vaccination.
How Long Does MenACWY Protection Last?
The MenACWY vaccine has a better-established duration of protection than MenB, largely because conjugate vaccines of this type have been used for longer. Protection from MenACWY lasts approximately 5 years. This is why the NHS gives it to teenagers at age 14 — timed so that protection covers the highest-risk years of 18–23 when students enter university and engage in the close-contact social behaviours that facilitate meningococcal transmission. If you received MenACWY at age 14, your protection is likely still reasonable through your early twenties but may be waning by your mid-twenties. If you are over 20 and received the vaccine at 14, and you remain in a higher-risk group (for example, you are still at university, living in shared accommodation, or planning travel to the meningitis belt), discussing a booster with your doctor is sensible. For travellers, Saudi Arabia requires proof of MenACWY vaccination within the previous 5 years for Hajj and Umrah pilgrims — reflecting the known duration of protection.
The Booster Question: Where Things Stand in 2026
There is currently no routine NHS booster programme for either MenB or MenACWY in the general population. This is a policy gap that the Kent outbreak has brought into sharp focus. The JCVI — the independent expert committee that advises the government on vaccination policy — has been asked by Health Secretary Wes Streeting to "re-examine eligibility for meningitis vaccines" following the outbreak. This review could potentially lead to recommendations for adolescent MenB booster doses, a catch-up programme for teenagers, or broader changes to the immunisation schedule. As of 24 March 2026, no policy change has been announced. Meningitis Now, the UK's leading meningitis charity, has been campaigning for adolescent MenB vaccination through their "No Plan B for MenB" initiative, calling for routine vaccination of teenagers and a booster programme from 2030. For individuals with high-risk medical conditions (asplenia, complement disorders, immunosuppression), booster doses may already be recommended by your specialist — speak to your consultant or GP if you are in this group and unsure. For everyone else, the decision about whether to seek a private booster depends on your individual risk assessment. A doctor at The Online GP by The Wellness can review your vaccination history, assess your current risk factors, and advise on whether additional doses are appropriate.
Book a Vaccination Review — WhatsApp →
What This Means for Different Age Groups
Children vaccinated as babies (born since 2015): Your child is well protected during infancy and early childhood. As they approach adolescence, protection may wane. Keep an eye on JCVI guidance — booster recommendations may emerge in the coming years. In the meantime, ensure their MenACWY vaccination at age 14 is not missed. Teenagers (14–18): If born before 2015, you are almost certainly unvaccinated against MenB. If born after 2015, your infant vaccination may offer some residual protection, but this is uncertain. Whether born before or after 2015, private MenB vaccination is worth considering before entering university. University students (18–25): The highest-risk group after infants. If you have never been vaccinated against MenB, doing so now provides the most protection during your highest-risk years. If you received MenACWY at 14, your protection is likely still active but will begin waning in your twenties.Adults over 25: If you were vaccinated against MenB privately in your late teens or early twenties, your protection may be waning. If you were never vaccinated, you have no protection. Consider vaccination or a booster based on your current risk factors — healthcare work, shared accommodation, travel, or medical conditions. The Online GP by The Wellness holds a direct supplier relationship with the vaccine manufacturer, which allows us to secure stock more quickly than many providers during the current shortage. Rates reflect the elevated procurement environment, but our doctors can discuss what makes sense for your specific situation. Contact us to check current availability.
Check Availability — WhatsApp → Same-Day GP Appointment — WhatsApp → Email: team@thewellnesslondon.com
How Quickly Does the Vaccine Start Working?
If you are considering vaccination now — perhaps prompted by the Kent outbreak — understanding the timeline to protection matters. After the first dose of Bexsero, your immune system begins producing antibodies within about 2 weeks. This provides some early protection, though not the full level achieved after the complete course. The second dose (given at least 4 weeks later on the accelerated schedule, or at 6 months on the standard schedule) significantly boosts antibody levels. It takes approximately 2 more weeks after the second dose for antibodies to reach their peak. This means full protection is achieved roughly 6–8 weeks after starting the course on the accelerated schedule, or approximately 7 months on the standard schedule. UKHSA noted during the Kent outbreak that "it typically takes around one to two weeks for immune responses to develop" after each dose, and urged eligible individuals to come forward "as soon as possible." Even a single dose provides some protection, so starting the course now is worthwhile even if you cannot complete it immediately. Partial protection is better than none.
Frequently Asked Questions
How long does the MenB vaccine last? Strong protection for at least 1–2 years, with antibody levels declining most rapidly in the first 12 months. Some immune memory persists longer. The exact long-term duration is still being studied.
How long does MenACWY last? Approximately 5 years. If vaccinated at 14, protection may be waning by your early twenties.
Do I need a booster? There is no routine NHS booster currently. The JCVI is reviewing this following the Kent outbreak. High-risk individuals may need boosters — ask your specialist. For others, a doctor can assess your individual situation.
Does the childhood vaccine still protect teenagers? Uncertain. Antibody levels decline over time and may not provide meaningful protection by adolescence. The JCVI is evaluating whether adolescent boosters are needed.
Should I get vaccinated again if I had MenB as a baby? Discuss with a doctor. If you are entering university or living in shared accommodation, a booster or repeat course may be appropriate.
How quickly does the vaccine work? Some protection from ~2 weeks after first dose. Full protection ~2 weeks after the second dose. On the accelerated schedule, full protection from roughly 6–8 weeks after starting.
Can I get a booster privately? Yes. The Online GP by The Wellness can assess your history and advise on additional doses. We hold a direct manufacturer supply relationship. Contact us on WhatsApp (+44 7961 280835) to discuss.
The Online GP by The Wellness provides private doctor-led healthcare from our Marylebone clinic. Contact us on WhatsApp at +44 7961 280835 or email team@thewellnesslondon.com. If you suspect meningitis symptoms, call 999 immediately.
References
UKHSA. Notified cases of invasive meningococcal disease — statistical releases. GOV.UK. Updated 23 March 2026.
UKHSA. Who is eligible for the MenB vaccine and do I need it myself? UKHSA blog. 20 March 2026.
Scientific American. UK's deadly meningitis outbreak shows importance of vaccination. 21 March 2026.
Meningitis Now. No Plan B for MenB campaign. 2026.
European Medicines Agency. Bexsero EPAR — immunogenicity and duration data. Updated 2025.
GSK. Bexsero Summary of Product Characteristics. EMC. 2025.
Wikipedia. 2026 Kent meningitis outbreak — vaccine duration. Updated 22 March 2026.
